Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.

Journal Article (Journal Article)

Circulating tumour DNA (ctDNA) has the potential to be a specific biomarker for the monitoring of tumours in patients with colorectal cancer (CRC). Here, our aim was to develop a personalised surveillance strategy to monitor the clinical course of CRC after surgery. We developed patient-specific ctDNA assays based on multiplexed detection of somatic mutations identified from patient primary tumours, and applied them to detect ctDNA in 44 CRC patients, analysing a total of 260 plasma samples. We found that ctDNA detection correlated with clinical events - it is detectable in pre-operative but not post-operative plasma, and also in patients with recurrent CRC. We also detected ctDNA in 11 out of 15 cases at or before clinical or radiological recurrence of CRC, indicating the potential of our assay for early detection of metastasis. We further present data from a patient with multiple primary cancers to demonstrate the specificity of our assays to distinguish between CRC recurrence and a second primary cancer. Our approach can complement current methods for surveillance of CRC by adding an individualised biological component, allowing us not only to point to the presence of residual or recurrent disease, but also attribute it to the original cancer.

Full Text

Duke Authors

Cited Authors

  • Ng, SB; Chua, C; Ng, M; Gan, A; Poon, PS; Teo, M; Fu, C; Leow, WQ; Lim, KH; Chung, A; Koo, S-L; Choo, SP; Ho, D; Rozen, S; Tan, P; Wong, M; Burkholder, WF; Tan, IB

Published Date

  • January 19, 2017

Published In

Volume / Issue

  • 7 /

Start / End Page

  • 40737 -

PubMed ID

  • 28102343

Pubmed Central ID

  • PMC5244357

Electronic International Standard Serial Number (EISSN)

  • 2045-2322

Digital Object Identifier (DOI)

  • 10.1038/srep40737


  • eng

Conference Location

  • England